Head-to-head · WeighScore
Eden vs SexyMD
The verdict
Eden takes it — 81.6/100 to 60.3/100.
Eden grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. High-disclosure, high-oversight compounded program with the cleanest verification signals.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Eden | SexyMD |
|---|---|---|
| WeighScore | 81.6/100 | 60.3/100 |
| Grade | B− | C |
| Site position | #16 | #369 |
| Semaglutide | $239/mo | $269/mo (four-week plan; the $199 in every headline is the 48-week rate) |
| Tirzepatide | $349/mo | $369/mo (four-week plan; the $299 in every headline is the 48-week rate) |
| Coverage | All 50 states | 47 states (all except Arkansas, Mississippi and New Jersey) |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #16 · B−
FDAWarning letter issued to Eden Health International Inc. dba Eden in June 2026. See the FDA warning-letter database.
Strengths
- High verification confidence
- Nationwide
- Both molecules
Where it loses points
- Premium pricing
- Compounded only
Site position #369 · C
Strengths
- Publishes an exact exclusion list — all states except Arkansas, Mississippi and New Jersey — rather than a nationwide claim
- States both compounding classes in the Terms, so the class question is answered even though the pharmacy is not named
- Names the prescribing entity and the professional corporation behind it
- Sells two microdose products with their own published price tables rather than only as a discount tier
Where it loses points
- Every headline price is the 48-week commitment rate: $199 against a month-to-month figure of $269, and $299 against $369, with an asterisk that resolves to no footnote
- The same footer, on every page, says both that the service is available in all 50 states and that it is available in all states except three
- The two microdose products publish identical prices for their 4-, 8- and 12-week plans, in the same table format that carries real tiers elsewhere
- The microdose page contradicts itself on dosing frequency inside a single page
- Three unsourced and mutually inconsistent social-proof figures appear across the homepage, the footer and the product pages
- The checkout claims two patient counts for a single day that together exceed the total the site's own badge claims
- No pharmacy is named, and what the price includes is never itemized on any product page
Featured provider
Eden
Eden scores 81.6/100 (B−). High-disclosure, high-oversight compounded program with the cleanest verification signals.
Commercial relationships affect this placement. The score comparison above is separate.
FDAWarning letter issued to Eden Health International Inc. dba Eden in June 2026. See the FDA warning-letter database.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.